Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist

Neuropharmacology

Volumn 58, Issue 1, 2010, Pages 69-77

  Ring, Robert H ^a   Schechter, Lee E ^a   Leonard, Sarah K ^a   Dwyer, Jason M ^a   Platt, Brian J ^a   Graf, Radka ^a   Grauer, Steven ^a   Pulicicchio, Claudine ^a   Resnick, Lynn ^a   Rahman, Zia ^a   Sukoff Rizzo, Stacey J ^a   Luo, Bin ^a   Beyer, Chad E ^a   Logue, Sheree F ^a   Marquis, Karen L ^a   Hughes, Zoë A ^a   Rosenzweig Lipson, Sharon ^a  

^a PFIZER INC   (United States)

Author keywords

Anxiety; Autistic spectrum disorders; Depression; Oxytocin; Schizophrenia; Vasopressin

Indexed keywords

1 [1 [4 (1 ACETYL 4 PIPERIDINYLOXY) 2 METHOXYBENZOYL] 4 PIPERIDINYL]BENZ[D][1,3]OXAZIN 2 ONE; 4 (3,5 DIHYDROXYBENZYL) N [2 METHYL 4 ((1 METHYL 4,10 DIHYDROPYRAZOLO[3,4 B][1,5]BENZODIAZEPIN 5(1H) YL)CARBONYL)BENZYL]PIPERAZINE 1 CARBOXAMIDE; AMPHETAMINE; DIZOCILPINE; FLUOXETINE; HALOPERIDOL; HORMONE RECEPTOR STIMULATING AGENT; OXYTOCIN; OXYTOCIN RECEPTOR; OXYTOCIN RECEPTOR STIMULATING AGENT; RISPERIDONE; UNCLASSIFIED DRUG; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; WAY 162720; WAY 267464;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; AUDITORY STIMULATION; AUTISM; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DEPRESSION; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIA; IMMOBILIZATION; MALE; MAZE TEST; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREPULSE INHIBITION; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA; STARTLE REFLEX; STRESS; TRANQUILIZING ACTIVITY;

ACOUSTIC STIMULATION; ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CHO CELLS; CRICETINAE; CRICETULUS; FEVER; HINDLIMB SUSPENSION; HUMANS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; NEURAL INHIBITION; OXYTOCIN; PROTEIN BINDING; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OXYTOCIN; STARTLE REACTION; STRESS, PSYCHOLOGICAL;

EID: 71549136792     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.07.016     Document Type: Article

References (50)

1. Aron C., Simon P., Larousse C., and Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10 (1971) 459-469
2. Altemus M. Neuropeptides in anxiety disorders. Effects of lactation. Ann. N. Y. Acad. Sci. 771 (1995) 697-707
3. Amico J.A., Vollmer R.R., Karam J.R., Lee P.R., Li X., Koenig J.I., and McCarthy M.M. Centrally administered oxytocin elicits exaggerated grooming in oxytocin null mice. Pharmacol. Biochem. Behav. 78 (2004) 333-339
4. Argiolas A., and Gessa G.L. Central functions of oxytocin. Neurosci. Biobehav. Rev. 15 (1991) 217-231
5. Arletti R., and Bertolini A. Influence of protease inhibitors on the antidepressant activity of oxytocin. Neuropeptides 10 (1987) 241-248
6. Arletti R., and Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 41 (1987) 1725-1730
7. Ashworth D.M., Batt A.R., Baxter A.J., Broqua P., Haigh R.M., Hudson P., Heeney C.M.S., Laporte R., Penson A., Pitt G.R.W., Robson P.A., Rooker D.P., Tartar A.L., Yea C.M., and Roe M.B. Nonpeptide oxytocin agonists. Drugs Future 31 (2006) 345-353
8. Bakharev V.D., Tikhomirov S.M., and Lozhkina T.K. Psychotropic properties of oxytocin. Neurosci. Behav. Physiol. 16 (1986) 160-164
9. Bale T.L., Davis A.M., Auger A.P., Dorsa D.M., and McCarthy M.M. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J. Neurosci. 21 (2001) 2546-2552
10. Bartz J.A., and Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. Prog. Brain Res. 170 (2008) 451-462
11. Batt, A.R., Ashworth, A.R., Baxter, A.J., Haigh, R.M., Hudson, P., Heeney, C.M.S., Penson, A.M., Pitt, G.R.W., Robson, P.A., Rooker, D.P., Tartar, A.L., Yea, C.M., Roe, M.B., 2003. Non-peptide piperazine ureas as oxytocin agonists. In: 226th ACS National Meeting, New York City, NY.
12. Bielsky I.F., and Young L.J. Oxytocin, vasopressin, and social recognition in mammals. Peptides 25 (2004) 1565-1574
13. Bourin M., Hascoet M., Mansouri B., Colombel M.C., and Bradwejn J. Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J. Psychiatry Neurosci. 17 (1992) 72-77
14. Bujanow W. Hormones in the treatment of psychoses. Br. Med. J. 4 (1972) 298
15. Bujanow W. Letter: is oxytocin an anti-schizophrenic hormone?. Can. Psychiatr. Assoc. J. 19 (1974) 323
16. Burbach J.P., De Kloet E.R., and De Wied D. Oxytocin biotransformation in the rat limbic brain: characterization of peptidase activities and significance in the formation of oxytocin fragments. Brain Res. 202 (1980) 401-414
17. Burbach J.P., Bohus B., Kovacs G.L., Van Nispen J.W., Greven H.M., and De Wied D. Oxytocin is a precursor of potent behaviourally active neuropeptides. Eur. J. Pharmacol. 94 (1983) 125-131
18. Burbach J.P., and Lebouille J.L. Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanisms of proteolysis. J. Biol. Chem. 258 (1983) 1487-1494
19. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
20. Demitrack M.A., and Gold P.W. Oxytocin: neurobiologic considerations and their implications for affective illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 12 Suppl. (1988) S23-S51
21. Engelmann M., Ebner K., Wotjak C.T., and Landgraf R. Endogenous oxytocin is involved in short-term olfactory memory in female rats. Behav. Brain Res. 90 (1998) 89-94
22. Epperson C.N., McDougle C.J., and Price L.H. Intranasal oxytocin in obsessive-compulsive disorder. Biol. Psychiatry 40 (1996) 547-549
23. Feifel D., and Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl.) 141 (1999) 93-98
24. Frasch A., Zetzsche T., Steiger A., and Jirikowski G.F. Reduction of plasma oxytocin levels in patients suffering from major depression. Adv. Exp. Med. Biol. 395 (1995) 257-258
25. Guastella A.J., Mitchell P.B., and Dadds M.R. Oxytocin increases gaze to the eye region of human faces. Biol. Psychiatry (2007)
26. Hascoet M., Bourin M., Colombel M.C., Fiocco A.J., and Baker G.B. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol. Biochem. Behav. 65 (2000) 339-344
27. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., and Wasserman S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry (2006)
28. Insel T.R., and Shapiro L.E. Oxytocin receptor distribution reflects social organization in monogamous and polygamous voles. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5981-5985
29. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., and Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J. Neurosci. 25 (2005) 11489-11493
30. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., and Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30 (2005) 1883-1894
31. Leonard S.K., Dwyer J.M., Sukoff Rizzo S.J., Platt B., Logue S.F., Neal S.J., Malberg J.E., Beyer C.E., Schechter L.E., Rosenzweig-Lipson S., and Ring R.H. Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl.) 197 (2008) 601-611
32. Malberg J.E., Platt B., Rizzo S.J., Ring R.H., Lucki I., Schechter L.E., and Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32 (2007) 2360-2368
33. Mantella R.C., Vollmer R.R., Li X., and Amico J.A. Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology 144 (2003) 2291-2296
34. Marazziti D., and Catena Dell'osso M. The role of oxytocin in neuropsychiatric disorders. Curr. Med. Chem. 15 (2008) 698-704
35. McCarthy M.M., McDonald C.H., Brooks P.J., and Goldman D. An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol. Behav. 60 (1996) 1209-1215
36. Neumann I.D. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J. Neuroendocrinol. 20 (2008) 858-865
37. Nowakowska E., Kus K., Bobkiewicz-Kozlowska T., and Hertmanowska H. Role of neuropeptides in antidepressant and memory improving effects of venlafaxine. Pol. J. Pharmacol. 54 (2002) 605-613
38. Numan M., and Insel T.R. The Neurobiology of Parental Behavior (2003), Springer, Secaucus, NJ
39. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 (1985) 149-167
40. Ring R.H. The Central Vasopressinergic and Oxytocinergic Systems as Targets for Psychiatric Drug Development. Neurohypophyseal Hormones: From Genomics and Physiology to Disease (2005), American Physiological Society, Steamboat Springs, Colorado p. 162
41. Ring R.H., Malberg J.E., Potestio L., Ping J., Boikess S., Luo B., Schechter L.E., Rizzo S., Rahman Z., and Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl.) 185 (2006) 218-225
42. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Marechal P., Pequeux C., Ansseau M., and Legros J.J. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology (2007)
43. Uvnäs-Moberg K., Widstrom A.-M., Nissen E., and Bjorvell H. Personality traits in women 4 days postpartum and their correlation with plasma levels of oxytocin and prolactin. J. Psychosom. Obstet. Gynaecol. 11 (1990) 261-273
44. Uvnas-Moberg K., Bjokstrand E., Hillegaart V., and Ahlenius S. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology (Berl.) 142 (1999) 95-101
45. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., and De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17 (1997) 284-292
46. Williams P.D., Clineschmidt B.V., Erb J.M., Freidinger R.M., Guidotti M.T., Lis E.V., Pawluczyk J.M., Pettibone D.J., Reiss D.R., Veber D.F., et al. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J. Med. Chem. 38 (1995) 4634-4636
47. Windle R.J., Shanks N., Lightman S.L., and Ingram C.D. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 138 (1997) 2829-2834
48. Winslow J.T., Hearn E.F., Ferguson J., Young L.J., Matzuk M.M., and Insel T.R. Infant vocalization, adult aggression, and fear behavior of an oxytocin null mutant mouse. Horm. Behav. 37 (2000) 145-155
49. Yoshida M., Takayanagi Y., Inoue K., Kimura T., Young L.J., Onaka T., and Nishimori K. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J. Neurosci. 29 (2009) 2259-2271
50. 2+ signaling using an enabling chimeric G-protein. Eur. J. Pharmacol. 472 (2003) 33-38